Skip to main content
. 2012 Aug 17;7(8):e43369. doi: 10.1371/journal.pone.0043369

Figure 3. Distribution of melanoma patients according to pathway somatic mutations.

Figure 3

(a) Percentages of melanomas that have: a BRAFV600 mutation without a PI3K pathway mutation, a BRAFV600 mutation with a PI3K pathway mutation, a NRAS mutation without a PI3K pathway mutation, a NRAS mutations with a PI3K pathway mutation, and a PI3K pathway mutation with wild-type BRAFV600 and NRAS. (b) Number of patients who carried the somatic mutations identified by Sanger sequencing.